Novo Nordisk Stock Plunges on Disappointing Weight Loss Drug Trial Results
Novo Nordisk shares plunged after its new weight loss drug, CagriSema, fell short of weight loss targets in a clinical trial. Although meeting the primary endpoint, the drug didn’t achieve the anticipated 25% weight loss, impacting investor confidence.
Novo Nordisk Stock Plunges on Disappointing Weight Loss Drug Trial Results Read More »